Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 172

1.

Mild Chronic Hyponatremia in the Ambulatory Setting: Significance and Management.

Rondon-Berrios H, Berl T.

Clin J Am Soc Nephrol. 2015 Jun 24. pii: CJN.00170115. [Epub ahead of print]

PMID:
26109207
2.

Vasopressin antagonists.

Berl T.

N Engl J Med. 2015 Jun 4;372(23):2207-16. doi: 10.1056/NEJMra1403672. Review. No abstract available.

PMID:
26039601
3.

Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.

Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, Kato A, Shimizu M.

J Am Soc Nephrol. 2015 Jul;26(7):1732-46. doi: 10.1681/ASN.2014010042. Epub 2014 Oct 27.

PMID:
25349205
4.

Dysnatremias in patients with kidney disease.

Combs S, Berl T.

Am J Kidney Dis. 2014 Feb;63(2):294-303. doi: 10.1053/j.ajkd.2013.09.017. Epub 2013 Nov 14. Review.

PMID:
24239050
5.

Combined angiotensin inhibition for the treatment of diabetic nephropathy.

Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators.

N Engl J Med. 2013 Nov 14;369(20):1892-903. doi: 10.1056/NEJMoa1303154. Epub 2013 Nov 9. Erratum in: N Engl J Med. 2014;158:A7255.

6.

Severe lupus nephritis: the predictive value of a ≥ 50% reduction in proteinuria at 6 months.

Korbet SM, Lewis EJ; Collaborative Study Group.

Nephrol Dial Transplant. 2013 Sep;28(9):2313-8. doi: 10.1093/ndt/gft201. Epub 2013 Jun 19.

PMID:
23787551
7.

Where vaptans do and do not fit in the treatment of hyponatremia.

Jovanovich AJ, Berl T.

Kidney Int. 2013 Apr;83(4):563-7. doi: 10.1038/ki.2012.402. Epub 2012 Dec 19. Review.

PMID:
23254896
8.

An elderly patient with chronic hyponatremia.

Berl T.

Clin J Am Soc Nephrol. 2013 Mar;8(3):469-75. doi: 10.2215/CJN.03100312. Epub 2012 Oct 4. Review.

9.

Differential diagnosis of hyponatraemia.

Thompson C, Berl T, Tejedor A, Johannsson G.

Best Pract Res Clin Endocrinol Metab. 2012 Mar;26 Suppl 1:S7-15. doi: 10.1016/S1521-690X(12)70003-9.

PMID:
22469249
10.

Mortality and serum sodium in CKD--yet another U‑shaped curve.

Jovanovich A, Berl T.

Nat Rev Nephrol. 2012 May;8(5):261-3. doi: 10.1038/nrneph.2012.65.

PMID:
22473511
11.

An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.

Smink PA, Bakker SJ, Laverman GD, Berl T, Cooper ME, de Zeeuw D, Lambers Heerspink HJ.

J Hypertens. 2012 May;30(5):1022-8. doi: 10.1097/HJH.0b013e32835200f9.

PMID:
22388234
12.

Complete remission in severe lupus nephritis: assessing the rate of loss in proteinuria.

Korbet SM, Lewis EJ; Collaborative Study Group.

Nephrol Dial Transplant. 2012 Jul;27(7):2813-9. doi: 10.1093/ndt/gfr741. Epub 2011 Dec 23.

13.

Pyridorin in type 2 diabetic nephropathy.

Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB; Collaborative Study Group.

J Am Soc Nephrol. 2012 Jan;23(1):131-6. doi: 10.1681/ASN.2011030272. Epub 2011 Oct 27.

14.

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.

Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC; Collaborative Study Group.

J Am Soc Nephrol. 2012 Jan;23(1):123-30. doi: 10.1681/ASN.2011040378. Epub 2011 Oct 27.

15.

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8.

16.

Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.

Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group.

Am J Kidney Dis. 2011 Nov;58(5):729-36. doi: 10.1053/j.ajkd.2011.06.020. Epub 2011 Aug 26. Erratum in: Am J Kidney Dis. 2012 Feb;59(2):318.

PMID:
21872376
17.

Is osmotic demyelination a concern dialyzing hyponatremic patients?

Sirota JC, Berl T.

Semin Dial. 2011 Jul-Aug;24(4):407-9. doi: 10.1111/j.1525-139X.2011.00899.x. Epub 2011 Jul 29. No abstract available.

PMID:
21801217
18.

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.

Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ.

Eur Heart J. 2011 Jun;32(12):1493-9. doi: 10.1093/eurheartj/ehr017. Epub 2011 Mar 18.

19.

Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion.

Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS; SALT Investigators.

Eur J Endocrinol. 2011 May;164(5):725-32. doi: 10.1530/EJE-10-1078. Epub 2011 Feb 11.

20.

Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.

Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK.

Circ Heart Fail. 2011 Jan;4(1):18-26. doi: 10.1161/CIRCHEARTFAILURE.109.932558. Epub 2010 Oct 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk